Free Access
Med Sci (Paris)
Volume 31, Number 8-9, Août–Septembre 2015
Page(s) 707 - 708
Section Éditorial
Published online 04 September 2015
  1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893 ; 105 : 487–511. [CrossRef] [Google Scholar]
  2. Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909 ; 5 : 273–290. [Google Scholar]
  3. Old LJ, Clark DA, Benacerraf B. Effect of bacillus Calmette Guérin infection on transplanted tumors in the mouse. Nature 1959 ; 184 : 291–292. [CrossRef] [PubMed] [Google Scholar]
  4. Mathé G, Bernard J, Schwarzenberg L, et al. Trial treatment of patients afflicted with acute leukemia in remission with total irradiation followed by homologous bone marrow transfusion. Rev Fr Etud Clin Biol 1959 ; 4 : 675–704. [PubMed] [Google Scholar]
  5. Burnet MF. Cancer: a biological approach. I. The processes of control. Br Med J 1957 ; 780 : 779–786. [CrossRef] [Google Scholar]
  6. Thomas L. Delayed hypersensitivity in health and disease. In : Lawrence HS, ed. Cellular and humoral aspects of the hypersensitive states. New York : Hoeber-Harper, 1959 : 529–533. [Google Scholar]
  7. Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975 ; 256 : 495–497. [CrossRef] [PubMed] [Google Scholar]
  8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960–1964. [CrossRef] [PubMed] [Google Scholar]
  9. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008 ; 26 : 4410–4417. [CrossRef] [PubMed] [Google Scholar]
  10. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012 ; 12 : 298–306. [CrossRef] [PubMed] [Google Scholar]
  11. Topalian S, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015 ; 27 : 450–461. [CrossRef] [PubMed] [Google Scholar]
  12. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015 ; 33 : 2013–2020. [CrossRef] [PubMed] [Google Scholar]
  13. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015 ; 33 : 2004–2012. [CrossRef] [PubMed] [Google Scholar]
  14. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 ; 372 : 2006–2017. [CrossRef] [PubMed] [Google Scholar]
  15. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015 ; 372 : 2521–2532. [CrossRef] [PubMed] [Google Scholar]
  16. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008 ; 321 : 974–977. [CrossRef] [PubMed] [Google Scholar]
  17. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cells therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 ; 6 : 224ra25. [CrossRef] [PubMed] [Google Scholar]
  18. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. Nature 2014 ; 515 : 577–581. [CrossRef] [PubMed] [Google Scholar]
  19. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015 ; 348 : 69–74. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.